News
EYPT
11.26
-42.98%
-8.48
BUZZ-U.S. STOCKS ON THE MOVE-GoDaddy, Walt Disney, Aerovironment
U.S. Stock indexes extended last week's gains on Monday. Dow Jones Industrial Average was up 0.32% at 38,798.28. The top three S&P 500 percentage gainers were American Airlines Group, Tyson Foods. Investors see a greater chance of the Federal Reserve cutting interest rates this year after softer-than-expected jobs data.
Reuters · 1h ago
EyePoint's Setback In NPDR Does Not Bode Well For DME (Rating Downgrade)
Seeking Alpha · 1h ago
Spirit Airlines Posts Weak Results, Joins Integra LifeSciences, Bowlero And Other Big Stocks Moving Lower On Monday
Spirit Airlines shares dipped 9.8% to $3.3450 on Monday. The company reported a revenue decline of 6.2% in the first quarter. EyePoint Pharmaceuticals, Inc. Shares fell 37.7% after the company's Phase 2 trial of DURAVYU failed. The Nasdaq Composite gained over 100 points in today's session.
Benzinga · 3h ago
Why Perficient Shares Are Trading Higher By Around 53%? Here Are 20 Stocks Moving In Monday's Mid-Day Session
Shares of Perficient, Inc jumped 53% to $73.60 on Monday. The company disclosed an acquisition deal and first-quarter FY24 results. BioCryst Pharmaceuticals, Inc. Gained 19% in the mid-day session. EyePoint Pharmaceuticals dipped 37.7% in pre-market trading.
Benzinga · 3h ago
12 Health Care Stocks Moving In Monday's Intraday Session
NRX Pharmaceuticals (NASDAQ:NRXP) shares increased by 39.5% to $2.93 during Monday's regular session. The company's Q1 earnings report came out 4 days ago. TC BioPharm (Holdings) stock moved upwards by 35.61% and Outset Medical stock rose 26.15%. Lyra Therapeutics shares decreased by 86.3% during the regular session to $0.55.
Benzinga · 3h ago
Monday Sector Laggards: Food, Drugs
NASDAQ · 3h ago
BUZZ-U.S. STOCKS ON THE MOVE-NAPCO Security Technologies, Outset Medical, US energy sector
Wall Street's main stock indexes gained on Monday as expectations of interest rate cuts grew stronger. The Dow Jones Industrial Average was up 0.06% at 38,699.88. The top three S&P 500 percentage gainers were Tyson Foods, Uber and Facebook.
Reuters · 4h ago
Nasdaq Jumps 100 Points; Tyson Foods Sales Miss Views
U.S. Stocks traded higher on Monday. The Dow traded up 0.25% while the NASDAQ rose 0.64%. Tyson Foods Inc reported weaker-than-expected sales for its second quarter. Energy shares rose by 1.5% on Monday; energy shares rose in trading on Friday. European shares were higher today.
Benzinga · 4h ago
EyePoint Pharmaceuticals Down Over 34%, on Pace for Largest Percent Decrease Since November 2011 -- Data Talk
EyePoint Pharmaceuticals, Inc. Is currently at $13.00, down $6.74 or 34.14%. Down two consecutive days; down 34.8% over this period. Down 96.76% from its all-time closing high of $401.60. Would be lowest close since Dec. 1, 2023.
Dow Jones · 5h ago
NanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare movers
Healthcare On the Move NanoViricides, Outset Medical, EyePoint Pharmaceuticals among healthcare movers. S&P 500 Health Care Sector +0.28% to 1645.07. Pharmaceuticals, Biotechnology & Life Science contributes 58% to index.
Seeking Alpha · 6h ago
BUZZ-U.S. STOCKS ON THE MOVE-U.S. Steel, Freshpet, oil stocks
Wall Street was poised for a higher open on Monday. Dow e-minis were up 0.36% ahead of the open. U.S. Steel Corp up 1.5% after surprise Q1 profit rise. Freshpet, oil stocks also rise. Investors priced in a greater chance of the Fed cutting interest rates this year.
Reuters · 6h ago
EyePoint tumbles 30% premarket on failed Phase 2 study
EyePoint tumbles 30% premarket on failed Phase 2 study for its eye drug Duravyu. The company says the drug failed to meet its primary endpoint in the treatment of non-proliferative diabetic retinopathy. EyePoint remains on track to start a Phase 3 study of the drug in AMD.
Seeking Alpha · 6h ago
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
EyePoint Pharmaceuticals Inc. Announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu in patients with non-proliferative diabetic retinopathy. The trial did not meet the pre-specified primary endpoint. The drug has a favorable safety and tolerability profile.
Benzinga · 7h ago
Health Care Sector Update for 05/06/2024: XLV, IBB, BNTX, EYPT, KRYS
NASDAQ · 7h ago
Market-Moving News for May 6th
EyePoint Pharmaceuticals shares are trading lower after the company's Phase 2 PAVIA trial of DURAVYU did not meet its primary endpoint. XBP Europe Holdings shares trading higher after winning a $40 million contract for His Majesty's Passport Office. Freshpet shares are Trading higher after reporting better-than-expected Q1 results.
Benzinga · 7h ago
GME, ONVO and POAI among pre-market losers
GlycoMimetics -78% announces results of phase 3 study of Uproleselan in refractory. Meta Materials -30% to lay off 80% of its employees. Safe & Green Holdings Corp -24% announces pricing of $4 million private placement. GME, ONVO and POAI among pre-market losers.
Seeking Alpha · 7h ago
BUZZ-EyePoint Pharma down as eye drug misses main goal in mid-stage trial
EyePoint Pharmaceuticals shares fall 31% to $13.63 premarket. Company says its experimental eye drug misses main goal in mid-stage trial. EyePoint's drug is an early-stage form of diabetic retinopathy. Stock down 14.6% YTD.
Reuters · 7h ago
12 Health Care Stocks Moving In Monday's Pre-Market Session
Monogram Orthopaedics (NASDAQ:MGRM) stock increased by 19.1% to $2.31 during Monday's pre-market session. Allarity Therapeutics shares rose by 13.99% during the session. Sunshine Biopharma and Addex Therapeutic shares also moved upwards. GlycoMimetics shares decreased by 78.7% in the pre- market session.
Benzinga · 8h ago
BUZZ-U.S. STOCKS ON THE MOVE-Paramount, Occidental Petroleum, Perficient
U.S. Stock index futures edged higher on Monday, pointing to more gains on Wall Street. Traders priced in a higher chance of the Federal Reserve cutting interest rates this year. Paramount Global, Occidental Petroleum, Perficient are among the day's top stocks.
Reuters · 8h ago
EyePoint Pharmaceuticals Shares Slide 32% on Duravyu Trial Missing Primary Endpoint
EyePoint Pharmaceuticals shares slide 32% after topline results from a Phase 2 clinical trial don't meet primary endpoint. The stock is down 15% on the year so far. Duravyu in non-proliferative diabetic retinopathy didn't meet the primary endpoint in the trial.
Dow Jones · 8h ago
More
Webull provides a variety of real-time EYPT stock news. You can receive the latest news about Eyepoint Pharmac through multiple platforms. This information may help you make smarter investment decisions.
About EYPT
EyePoint Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the business of developing and commercializing ophthalmic products for the treatment of eye diseases. The Company's pipeline leverages its Durasert technology (Durasert) for sustained intraocular drug delivery, including delivery of EYP-1901, is an investigational sustained delivery treatment for anti-vascular endothelial growth factor (anti-VEGF) mediated retinal diseases. Its additional pipeline programs include EYP-2301, a promising TIE-2 agonist, razuprotafib, formulated in Durasert E to potentially improve outcomes in serious retinal diseases. EYP-1901 is presently in Phase 2 clinical trials as a sustained delivery treatment for wet age-related macular degeneration (wet AMD), no proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The Company’s other products include YUTIQ, and DEXYCU.